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Of all the countries in the world, why did you choose Taiwan to pursue your study? It is a question that I
(comments of the first author) have answered a thousand times. My first visit to a laboratory at National
Taiwan University opened my eyes to the possibilities of herbal medicine research, especially in the area
of veterinary medicine. It became my ambition to link the knowledge of Traditional Chinese Medicine
(TCM) and Ayurveda from the Indian subcontinent and their integration with other systems of medicine,
including Western medicine (WM), to achieve the concept of Sustainable Medicine, firstly for
animals and then for humans. The Ministry of Economic Affairs (MOEA) has implemented a technology
development program to quickly establish the key technologies, and this is a moment of opportunity for
Taiwan’s traditional herbal medicine industry to upgrade and transform itself. This paper, initially inten-
ded to be a student’s narration, has evolved into a multi-author treatise on the present state and likely
future scenario of herbal medicine research in Taiwan.
Keywords: herbal medicine – research – Taiwan
Introduction
The global trend of reliance on complementary and alternative
medicine (CAM) is reviving, thanks to evolving human intelli-
gence. Of course, the engine behind this initiative is the need
of a better and sustainable future (1,2). Providing evidence
has been the responsibility of thousands of researchers, while
disseminating the information (the hardest task) has been
shouldered by eCAM and other journals. Students are being
drawn to the fantastic unexplored world of diversity in our sur-
roundings, including medicine and the art of self-healing. The
student gives a different dimensional view of reality that is
often overlooked or bypassed. An increasing number of such
reports in journals (3) and web pages demonstrate that
this view is gradually receiving recognition. In our report, we
present the situation in Taiwan from the mixed impression of
a foreign student’s almost half a decade stay and the lifetime
experience of local experts.
Historical Background
The history and development of traditional Chinese medicine
(TCM) in Taiwan have been expounded earlier by many
writers; the most recent by Prof Chen and his group is very
informative (4). The beautiful island ‘Ilha Formosa’, as the
Portuguese mariners named it sailing to Japan from Macao,
is what we know today as Taiwan. It was during the end of
the Ming dynasty that large-scale migration from mainland
China took place. They brought with them the ancient art and
knowledge of TCM with over 2000 years of history. Aiding
that effort was the rich flora and fauna of Taiwan, and the local
knowledge of the aboriginal people. Initially researched from a
cultural and anthropological aspect, TCM, and more precisely
Chinese Herbal Medicine (CHM), has now topped the list as
a first priority in the blueprint for the development of biotech-
nology in Taiwan. Socioeconomic progress, since the early
time of mainland migration from the end of Ming dynasty to
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Taiwanese culture, now demonstrated by how closely TCM
has been incorporated into the daily lives of Taiwanese.
Traditional Chinese Medicine in Taiwan:
A Long Transition
The influx of mainly Han people from mainland China in
1664, led by the Ming loyalist Cheng Ch’eng-kung (Zheng
Chenggong, known in the West as Koxinga), is said to be the
beginning of Chinese influence in Taiwan, though significant
migration to Taiwan from the Chinese mainland began as early
as AD 500. Taiwan’s aboriginal people, who originated in
Austronesia and southern China, have lived in Taiwan for
12000 to 15000 years (http://www.historyofnations.net/asia/
taiwan.html). CHM and its conventional trading system came
along with the culture of central China. Slowly integrating
the local and indigenous knowledge of the island, in these
past 400 years TCM has gradually established strong roots in
Taiwanese society. The torch of the TCM profession is its
conventional form of trading that has been passing on from
master to pupil and from generation to generation in a closed
commerce group. The traditional HoLo (Fukien) way of life,
and its He Ro traditional medicine culture, with special social
status relegated to TCM physicians, is considered one reason
for the vigorous development of HM industry in Taiwan (5).
Migration and Japanese Colonial Rule
Further migration from Fujian and Guangdong provinces in
China to Taiwan during the 18th and 19th centuries supplanted
aborigines as the dominant population group. It was during
those harsh times when difficult journeys made people seek
medicine at whatever price, boosting the trade in HM.
During 50 years (1895–1945) of Japanese colonial rule, the
‘Japanization’ of the island included compulsory Japanese
education and the forced adoption of Japanese names by resid-
ents of Taiwan. One notable influence was the patronage of
Western Medicine (WM), which had by then already been
introduced into Taiwan by Christian missionaries. It was con-
tinued by the Nationalist Chinese (KMT) administration on
Taiwan, which came into power in 1945, after World War II.
During the 1950s, the KMT authorities implemented a far-
reaching and highly successful land reform program on
Taiwan, which resulted in overall development. The encour-
agement of economic reforms generated many entrepreneurs
who went on to become Taiwan’s first industrial capitalists.
Together with refugee businesspersons from the mainland,
theymanagedTaiwan’stransitionfromanagriculturaltoacom-
mercial and industrial economy. This transition also benefited
the rise of HM industry from the status of mortar and pestle to
mechanized and automatic units. Depleted by colonial sup-
pression, a shortage of traditional medical practitioners led
the government to regularize the licensing system by evalu-
ation. Though criticized by various medical professionals for
the lack of strict educational requirements, by 2001 this system
had rolled out 18229 candidates who successfully passed the
‘Qualification Examinations’, and out of them 3047 passed
the ‘Special Examinations’ for practicing TCM in Taiwan (6).
The Transition of Informal Practice into
Formal Education
Cheng in his recent work (6) nicely narrates the transition of
informal practices to formal education leading to the degree
of Doctor of Chinese Medicine (DCM) in the late 1960s
(1966). The course duration was 7 years (8 years since 1996)
and the candidates had to study both WM and TCM. The
program is facing some controversies in licensing and a strong
lobbying and anti-lobbying tussle is going on between the
practitioners of WM and CM. Finally, the government ruled
that the ‘Qualification Examinations for Taking the Examina-
tion of the DCM’ is to be cancelled in 2008 and the ‘Chinese
Medicine Special Examinations’ in 2011 (6).
Mainstream health workers are also encouraged to have
liberal views toward TCM (7). This is in view of the growing
ageing population of Taiwan above 65 years, which now
hovers  10% of the total population, and is estimated to reach
20% by 2031, outnumbering the young population (8).
The policy-makers are also concerned by survey findings that
most patients (85.39%) who use CM prescriptions were over
40 years of age (9). There is also a widening gap between
social status and health problems in the elderly population
(10), rising premiums for state health care and its unequal
distribution. Hence, from a student’s viewpoint, the transition
of HM in particular and TCM in general in Taiwan seems
to be fueled by dual intentions. Firstly, to cash in on the
competitive edge for economic benefits, and secondly to
preserve the cultural heritage aimed at managing a growing
aging population.
Governmental Initiatives
Global trends toward the use of TCM have also had an impact
on the young generation of Taiwanese, who have accepted the
strong yet safe healing power of TCM. Today’s CHM holds
the cumulative wisdom of the Chinese people over several
thousands of years. Close documentation of the long clinical
history has given big drug companies an opportunity to exploit
the benefits of both WM and CM. The field of herbal medicine
is also widely considered one of the brightest areas of
Taiwan’s emerging biotech industry and the development of
traditional CHM is recognized as one of the niche markets
for Taiwan. To this end, a ‘5-year Plan for the Industrial Tech-
nology Development of CHM’ was approved by the Executive
Yuan in 2000 and carried out in January 2001. To integrate
the efforts of the various organizations deemed responsible
for the development of HM (used synonymously for CHM
in this article) industry, the Program Office of HM was
established in 2002. It has taken up the responsibility of
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modernizing the HM industry in Taiwan. The modernization
attempt began in the mid-1980s when Taiwan, one of the tiger
economies of Asia, pumped in resources to shift from ‘can do’
to ‘shall do’ research initiatives (11).
The value of the local herbal medicine market has been
estimated at approximately NT$15–25 billion. Pharmaceutical
application shares 20% of that amount, with the rest of the
market taken up by food supplements. In 2001, imported her-
bal raw materials amounted to NT$1.8 billion, >80% of which
is imported from Mainland China. This raised the local pro-
duction value of Chinese medicine to NT$4.2 billion. The
import market of herbal medicine for that period was valued
at NT$10 million and the export market at NT$ 130 million,
while the domestic demand reached NT$ 4.08 billion
(this information was obtained from the report prepared by
the Netherlands Trade and Investment Office in Taipei at
http://www.ntio.org.tw/trade/Biotechnology.htm).
A Huge Commercial Potential has Gained the
Attention of Pharmaceutical Companies
The growing popularity of traditional remedies and its huge
commercial potential has gained the attention of the pharma-
ceutical industry. The global herbal medicine market, estim-
ated at roughly over US$23 billion in 2002, is slated to grow
>13% annually. It is further projected that the value of the
global herbal medicine market will break through the
US$40 billion mark by 2006, an opportunity Taiwan-based
companies are eager to cash in on. The government supports
this trend by boosting strategic plans and their execution, pled-
ging new investment of NT$3.5 billion toward the industry
over the next 5 years.
Government’s Role and Support
With promotional plans and government funding for a biotech-
nology industry, development of scientific herbal medicine
topped the priority list. Though it will be unfair and inaccurate
to say it that way, prominent steps of integrating the then emer-
ging field of biotechnology to CM research began in the mid-
dle of the last decade. The beginning of the new millennium
saw concrete steps. In 2000 the Ministry of Economic Affairs
(MOEA) was assigned the responsibility to integrate all related
governmental organizations to develop HM. Billions of NT
dollars in funds were set aside for the task of achieving the
goal of scientific development of HM and related technology
products.
A major boost to the HM industry came with the establish-
ment of the program office of HM in 2002, and a shot in the
arm was achieved with HM being integrated in the National
Science and Technology Program for Biotechnology and
Pharmaceuticals[informationusedfromRef.(12)].Theprogram
office of herbal medicine was set up with the task of coordin-
ating the work of various governmental research agencies
and publicize their works with an aim to internationalize
Taiwan’s herbal medicine industry. The government is cur-
rently pursuing the promotion of international cooperation. It
is offering incentives and opportunities to foreign companies
to encourage them to set up research centers in Taiwan or
seek collaborations with local companies. The transfer of tech-
nology is also on the agenda to assist the international standard
of herbal products production and achieve sellable technology.
An information service system has been launched to stream-
line up-to-date information on current progress in the field
globally, and government policies and guidelines are in place
for those who will benefit in the herbal medicine industry.
The domestic herbal industry and related technology develop-
ment encourage fair competition and alliances among local
industries in research and development.
The Herbal Medicine Industry in Taiwan is
Basking in its Competitive Edge
The herbal medicine industry in Taiwan is basking in the
competitive edge that is built on cultural, social, economical,
geopolitical and technological advantages, to name a few.
With thousands of years of accumulated knowledge and
experience in herbal medicine, there is a will to preserve it at
any cost, although in early communist China it was discour-
aged (13). A 5 year plan to modernize the existing HM
industry in Taiwan is pursued seriously by consigning three
major players to jointly develop key platform technologies
and create a congenial atmosphere. The three institutes chosen
for the task are the Biomedical Engineering Center (BMEC) of
ITRI, Development Center for Biotechnology (DCB) and
Pharmaceutical Industries Technology Development Center
(PITDC). The research focuses on diseases such as hepatitis,
asthma, immune modulation and stomach ulcers (14). With
the 5 year national master plan complete, the outcome of the
integration and its achievements are now under analysis.
R&D, Clinical Trials and Quality Products
Policy- and decision-makers involved in TCM research in
Taiwan are aware of the claim that CAM trials are non-
equivalent or inferior to those of conventional medicine.
Now, with charges of foul play in clinical studies and publica-
tions, conventional medicine has its own concerns (15). CAM
can be subjected to excellent trials, though certain problems
with funding (16) and practicality of conducting trials, as
with conventional medicine, need to be addressed (17). The
challenges in developing excellent new drugs from Chinese
Materia Medica (CMM) in the post-genomic era (18) will not
be easy to overcome.
Leading the Asian countries in revealing a new face of TCM
(19), Taiwan has Asia’s highest concentration of clinical trial
centers capable of handling clinical trials of the best standards.
The Center for Drug Evaluation (CDE) and the Department of
Health Committee on Chinese Medicine and Pharmacy
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the nine specialized herbal medicine clinical trial centers
throughout the island (12). CCMP has established TCM
clinical centers in 10 excellent teaching hospitals, with neces-
sary network configuration and standard operation procedures.
In addition, encouraging private sector involvement, the
committee has received 14 pharmaceutical companies’ IND/
NDA applications to conduct clinical trials, and after thorough
review by the committee six companies were reportedly given
a green light (20). The current state of imported new drugs
(IND) and new drug application (NDA) in Taiwan has been
made swifter, with the review time shortened from 9.9 months
(IND) and 2.9 months (NDA) in 1997 to 4.2 and 1.2 months,
respectively, in 2001 (21).
Good Clinical Practice and Good
Manufacturing Practice Implementation
The Taiwanese government is investing NT$200 million each
year for a period of 5 years to establish a general clinical
research center (GCRC) in Taiwan. Good clinical practice
(GCP) compliance has been a mandatory step in IND/NDA
clinical trials since its implementation in 1997. Strong
coordination of related agencies is emphasized in an attempt
to globalize efficient, safe and quality HM products and secur-
ing Taiwan’s position as a strong hub of R&D in the world. To
ensure adequate drug safety standards and to help local phar-
maceutical companies meet international standards, the
Department of Health (DOH) announced that it would enforce
the new Good Manufacturing Practice (GMP) regulations on
all domestic pharmaceutical companies engaging in the manu-
facturing of herbal medicine, starting from 1 March 2005. This
effort is intended to stop industry-damaging practices such as
the selling of spurious Chinese medicinal ingredients, adul-
teration of herbal medicine with Western pharmaceuticals,
the selling of herbal medicine on the streets and the broadcast
of commercials containing unsubstantiated claims about a
particular herbal product. There are currently 73 Chinese phar-
maceutical companies in Taiwan that already implement
GMP. The remaining 95 traditional pharmaceutical companies
were expected to join the crowd and start implementing GMP
from 1 March 2005. After the GMP implementation for both
WM and CM 25 years ago, this new GMP implementation
project for pharmaceutical companies manufacturing Chinese
medicine marks another milestone for the island’s medical
industry (22). To make available the best quality raw materials
for the herbal medicine industry, the government in Taiwan
plans to establish a quality assessment center for CM entering
Taiwan from China.
Integration of Ancient Tradition with
Modern Technology
Taiwan as a whole presents a museum view of this fine blend
of ancient culture and modern technology, and any alert eyes
can see it in every part of day-to-day activities including health
(23). Experts of TCM belief that while developing CMM as
modern medicine it should not be forgotten that the use of
CMM is always governed by the conformation dictated by
TCM diagnosis and principles. They are firm in their belief
and capable of influencing policy-makers in HM industry of
Taiwan that blending modern scientific technology to the
ancient traditionisthe way outforCMM based new medicines.
This is bound to help efficiently design, generate, and validate
in the mainstream pharmaceutical market of the 21st century
(24). Drug discovery and development in this age of rapid
strides in the field of genomic and proteomic technologies
have benefited from the high throughout screening. Taiwan,
with its top IT technology development, is making the best
use of every possible integration opportunity. They intend to
remainastepaheadtocreateopportunity,includingapplication
of bioinformatics data mining to ancient and rare TCM books.
With a government supported gene therapy program project
initiated in 1994 (25), genetic diseases and ethnicity based
drug development from HM is definitely under consideration.
Tissue (26), cDNA (27) and protein array for evaluation of
herbs is already an old story here. The integration spreads bey-
ond the field of clinical trial and areas of analysis, benefiting
preparation and administration. Integration for human health
care(28)eveninanimals(2)toattaintheconceptofsustainable
medicine based on the utilization of the best of all forms of
medication is an emerging school of thought in Taiwan.
Pattern of CHM Utilization in Taiwan
A utilization pattern for herbal medicine is just emerging in
Taiwan. Uninformed patients, unscrupulous traders, adulter-
ated preparations, unlicensed practitioners, and illegal sources
for herbal medicines have been blamed for creating a bad
image of HM use in Taiwan (29,30). A survey by Chen’s group
(10) reported that males (59.36%) were more likely to use
CHM than females (40.64%). The common primary ailments
for seeking CHM treatment were insomnia (15.58%), meno-
pause (5.22%), constipation, functional disorders of the
stomach and allergic rhinitis in the range of  5%. Successful
treatment by CHM has been reported in pediatric oncology
(31), topical medications (32), childhood bronchial asthma
(33) and a range of other ailments. Mostly herbal formulas
are prescribed (66.09%), with the average number of drugs
per CM prescription being 4.87 (10). The decision to cover
CHM treatment under National Health Insurance (NHI) in
1992 had a big impact on the pattern of CHM unitization in
Taiwan.
Taiwan has an excellent national health care system at a
cheaper rate than other industrialized countries, with each indi-
vidual paying an average of  $20 per month for full health
care coverage. That $20 a month includes maternity, dental,
vision and all medical visits. It even helps cover prescription
drug costs, which are dramatically lower in Taiwan than they
are in the United States. Taiwanese citizens receive care that
is nearly as good as the care received in the United States,
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an average American (http://www.newstarget.com/001896.
html). However, the drawbacks of the system in Taiwan
include unwise use of excess pills by those who are not very
ill. There is a lack of clear information about the overall
CHM utilization pattern in Taiwan, except for some survey
studies of general hospitals and elderly homes. It is noteworthy
that numbers of big general hospitals performing Western
medical treatment are beginning to set up Chinese medicine
departments. I sense a great danger of herb-medicine interac-
tion in elderly patients of Taiwan, as state covered prescription
medicine and cultural inclination for CHM make a deadly
cocktail if not used properly.
Chinese Herbal Medicine for Sex
Enhancement
Chinese men have always been interested in increasing virility
and sexual satisfaction to the extent of using any means pos-
sible, an aspect that has been well documented. Ancient
Chinese manuscripts are full of recipes for aphrodisiacs and
philters (34), while in the modern era anything from rhino
horn to mice testes ends up as medicine. One of the major
attractions for tourists in Taipei is the snake alley, in a famous
night market. Live snakes, tortoises, seafood, animal testes and
varieties of insects are offered for their believed sex enhancing
potentialities. Recent studies in the androgen status of middle
age and elderly Chinese men showed that the total testosterone
and sex hormone binding protein were lower in those suffering
from erectile dysfunction, which mirrored the findings from
other ethnic populations. However, a contrast reporting from
the work was the higher free testosterone in erectile dysfunc-
tion cases, indicating a possible ethnic difference (35). With-
out speculation of any possible link between the finding and
the seeking of virility boosting agents by middle-aged and eld-
erly Chinese men, it is true that this medical area has a huge
market in Taiwan.
Among the most probable underlying medical causes for the
problem is the stress of workaholic lifestyle and pollution of
industries and emission of over 8 million vehicles in Taiwan.
In the early half of the last decade, this market put Taiwan in
the limelight for the wrong reason. Stocks of rhinoceros horns
in Taiwan created a bad image in Taiwan. Imports of
 2000 kg of tiger bone to produce tiger bone wine each year
and restaurants in Taiwan selling tiger penis soup were some
of those thousands of news reports making the rounds in
international media during the period 1992–94 (36,37). The
results of the media highlights had severe effects on Taiwan’s
TCM trade and international relationships, even leading to
the invoking of the Pelly Amendment from the United States
and Taiwan losing more than US$30 000 000 per year (6).
Although rhinos and tigers in the jungles of Royal Chitwan
National Park, Nepal and other parks in India continue to die,
the Convention on International Trade in Endangered Species
of Wild Fauna and Flora has greatly changed the shape of
traditional aphrodisiac materials in TCM. Still, deer antlers,
horns of domestic animals, farmed bear gall bladder, etc. are
still available through an underground trafficking of illegal
substances.
Screening of herbs for their possible role in hormone
replacement therapy in menopause and andropause manage-
ment, and possible aphrodisiac roles, is gaining momentum
in Taiwan (38,39). In our own investigation of several herbal
medicines for potential steroidogenic activity, we have
screened over a hundred herbs both in vivo and in vitro to ana-
lyze their effect on steroid hormones (testosterone, progester-
one, cortisol). Utilizing advanced techniques, key enzymes
and proteins in the various steps of steroidogenesis within the
cells are minutely scrutinized to establish the signal transduc-
tion pathway for the active component in the potent herb
extract. Changes in the intracellular environment in the
steroidogenic cells due to aging and stress and experiments
with various herbal extracts to rectify the damage in an attempt
to create aging-regulating formulas are currently underway in
our research (40).
Herbal Medicine for Veterinary Use
In spite of the huge potentiality of business prospect of HM for
veterinary use, Taiwanese manufacturers have shied away
from investing on it. Reasons for such neglect are quite baf-
fling, but a major one is the lack of research in this field. To
promote research and awareness in this field the Chinese Soci-
ety of Traditional Veterinary Science (CSTVS) based in Taipei
is pushing hard. Regular training courses and seminars on the
possible incorporation of TCM for veterinary use are con-
ducted and they are starting to bear fruits. Acupuncture is
now becoming an integral part of the pet animal care in major
city clinics of Taiwan. Equine and bovine practice with TCM
is limited to failed cases of WM treatment, mostly related to
skeleto-muscular or gynaecological disorders. However, faint
voice on the need for sustainable animal farming awareness
is beginning to be raised in gathering of veterinarians. This
promises that in future use of TCM will be widely employed
in animal health care. Regional co-operation to hasten wider
acceptance is being mulled to establish safe food production
scenario for future. In such an attempt, Asian Society of
Traditional Veterinary Science (ASTVS) was formed with
representation from Japan, South Korea, China, Taiwan and
Nepal. Having said that, HM for veterinary use will only
get impetus if more research is allocated in this field, and
commercial production starts to tap the potential market.
Conclusion
The trend toward natural health methods has set off tremend-
ous changes in the international and domestic market of
Taiwan offering unprecedented opportunities for the develop-
ment of herbal medicine. Taiwan is taking full advantage of
the links to the ancient cumulative wisdom of the Chinese
eCAM 2006;3(1) 153people, extending over several thousands of years. Considered
one of the brightest areas of Taiwan’s emerging biotech
industry, advancement in CHM is growing with leaps and
bounds. With the global herbal medicine market estimated at
roughly US$23 billion in 2002 and slated to grow by >13%
annually, Taiwan knows where the cash is. It is further projec-
ted that the value of the global herbal medicine market will
break through the US$40 billion mark by 2006, and Taiwan
is striving to grab a major share of it. Although the government
is pumping in lot of resources toward the development of
CHM, its policy to push for biotechnology and integrated big
projects overlooks basic research. Taiwanese decision-
makers should learn lessons from the recent Korean debacle
in advance biotechnical science. With restrains in funding,
small researchers cannot sustain rigorous testing of the
medicinal properties of herbal extracts. In the same line, there
is much that the Taiwanese government can do to introduce
TCM therapy in animals kept both for food and companionship
purposes, acknowledging that the global use of medicine in
animals far exceeds that in humans. Hence, to sustain the
development of CHM, Taiwan needs to reflect on all the
shortcomings and push for greater reforms in quality research
and production. An effort must also be made to ensure that
the availability of raw materials for the herbal medicine
industry is protected in a sustainable way and that the rush
to biotech era medicine does not trample the grass roots
researchers who discover the new compounds.
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